Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma - PubMed (original) (raw)
Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma
Shixian Huang et al. Biomaterials. 2011 Oct.
Abstract
Gene therapy offers a promising cure of brain glioma and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is able to induce cell apoptosis of glioma selectively without affecting the normal cells. In this study, the nanoscopic high-branching dendrimer, polyamidoamine (PAMAM), was selected as the principal vector. Angiopep-2, which can target to the low-density lipoprotein receptor-related protein-1 (LRP1) expressed on BCECs and glial cells, was exploited as the targeting ligand to conjugate PAMAM via bifunctional polyethyleneglycol (PEG) and then complexed with the DNA, designated as PAMAM-PEG-Angiopep/DNA nanoparticles (NPs). The cellular uptake mechanism explored in glial cells showed that the DNA of PAMAM-PEG-Angiopep/DNA NPs entered into the nuclei through the endosome/lysosome pathway. The in vivo biodistribution of PAMAM-PEG-Angiopep/DNA NPs in the brain especially the tumor site was higher than that of PAMAM-PEG/DNA NPs and PAMAM/DNA NPs. Furthermore, the TUNEL analysis showed a more wide-extended apoptosis in the PAMAM-PEG-Angiopep/pORF-TRAIL NPs treated group, compared to other groups including commercial Temozolomide-treated one. The median survival time of PAMAM-PEG-Angiopep/pORF-TRAIL NPs and Temozolomide treated on brain tumor-bearing mice was 61 and 49 days respectively, significantly longer than that of other groups. Besides, the NPs suggested low cytotoxicity after in vitro transfection. Thus, the results showed that Angiopep-2 could be exploited as a specific ligand to cross the BBB and targeted to glial cells, and PAMAM-PEG-Angiopep/DNA NPs can be a potential non-viral delivery system for gene therapy of glial tumor.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
- Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer.
Ke W, Shao K, Huang R, Han L, Liu Y, Li J, Kuang Y, Ye L, Lou J, Jiang C. Ke W, et al. Biomaterials. 2009 Dec;30(36):6976-85. doi: 10.1016/j.biomaterials.2009.08.049. Epub 2009 Sep 17. Biomaterials. 2009. PMID: 19765819 - Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration.
Huang R, Ke W, Han L, Li J, Liu S, Jiang C. Huang R, et al. Biomaterials. 2011 Mar;32(9):2399-406. doi: 10.1016/j.biomaterials.2010.11.079. Epub 2010 Dec 24. Biomaterials. 2011. PMID: 21185076 - Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles.
Liu Y, Huang R, Han L, Ke W, Shao K, Ye L, Lou J, Jiang C. Liu Y, et al. Biomaterials. 2009 Sep;30(25):4195-202. doi: 10.1016/j.biomaterials.2009.02.051. Epub 2009 May 20. Biomaterials. 2009. PMID: 19467700 - PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery.
Luong D, Kesharwani P, Deshmukh R, Mohd Amin MCI, Gupta U, Greish K, Iyer AK. Luong D, et al. Acta Biomater. 2016 Oct 1;43:14-29. doi: 10.1016/j.actbio.2016.07.015. Epub 2016 Jul 12. Acta Biomater. 2016. PMID: 27422195 Review.
Cited by
- Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.
Meng J, Agrahari V, Youm I. Meng J, et al. J Neuroimmune Pharmacol. 2017 Mar;12(1):84-98. doi: 10.1007/s11481-016-9698-1. Epub 2016 Jul 23. J Neuroimmune Pharmacol. 2017. PMID: 27449494 Review. - Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy.
Tarach P, Janaszewska A. Tarach P, et al. Int J Mol Sci. 2021 Mar 13;22(6):2912. doi: 10.3390/ijms22062912. Int J Mol Sci. 2021. PMID: 33805602 Free PMC article. Review. - Overcoming the Blood-Brain Barrier: Successes and Challenges in Developing Nanoparticle -Mediated Drug Delivery Systems for the Treatment of Brain Tumours.
Ferraris C, Cavalli R, Panciani PP, Battaglia L. Ferraris C, et al. Int J Nanomedicine. 2020 Apr 30;15:2999-3022. doi: 10.2147/IJN.S231479. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32431498 Free PMC article. Review. - On the shuttling across the blood-brain barrier via tubule formation: Mechanism and cargo avidity bias.
Tian X, Leite DM, Scarpa E, Nyberg S, Fullstone G, Forth J, Matias D, Apriceno A, Poma A, Duro-Castano A, Vuyyuru M, Harker-Kirschneck L, Šarić A, Zhang Z, Xiang P, Fang B, Tian Y, Luo L, Rizzello L, Battaglia G. Tian X, et al. Sci Adv. 2020 Nov 27;6(48):eabc4397. doi: 10.1126/sciadv.abc4397. Print 2020 Nov. Sci Adv. 2020. PMID: 33246953 Free PMC article. - Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB.
Kimura S, Harashima H. Kimura S, et al. Pharmaceutics. 2020 Dec 15;12(12):1216. doi: 10.3390/pharmaceutics12121216. Pharmaceutics. 2020. PMID: 33334049 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous